The Impact of B-type natriuretic peptide (BNP) on Transplanted Liver Hemodynamics and Short-Term Prognosis: A Single-Center Big Data Retrospective Study

doi:10.37015/AUDT.2025.240031

Abstract

Abstract:

Objective: This study investigates the correlation between early B-type natriuretic peptide (BNP) levels and ultrasound hemodynamics following liver transplantation, with the aim of evaluating short-term prognosis.

Methods: We analyzed data from 924 patients who underwent liver transplantation between December 2012 and October 2022. Ustilizing the clinical liver transplantation ultrasound imaging database software V1.0 developed by Tianjin First Central Hospital, we recorded various ultrasonic dynamic parameters, including peak systolic velocity (PSV), end-diastolic velocity (EDV), peak systolic/diastolic flow velocity (S/D), resistance index (RI), pulsatility index (PI), and portal vein velocity (PVV). Additionally, BNP values were recorded within 24 hours post-surgery. We analyzed the correlation between ultrasound blood flow parameters and BNP levels. Patients were categorized into death and survival groups based on their prognosis at 3 months, and differences in blood flow parameters were compared between these groups. Furthermore, short-term prognosis was assessed based on blood flow parameters associated with diastolic blood flow.

Results: Negative correlations were observed between BNP and the resistance index (RI) and pulsatility index (PI) on the first day after surgery (r = -0.473, r = -0.602, both P < 0.05). Similar correlations were found on the fifth day post-surgery (r = -0.406, r = -0.518, both P < 0.05). Additionally, peak systolic velocity (PSV), end diastolic velocity (EDV), and BNP levels were significantly higher in the death group compared to the survival group on both the first and fifth days after surgery (all P < 0.05), while RI and PI were lower in the death group (both P < 0.05). The systolic/diastolic (S/D) ratio in the death group was also lower than that in the survival group on the first and fifth days post-surgery (both P = 0.001). Furthermore, the presence of early diastolic blood flow after surgery was not associated with short-term prognosis in either group (both P > 0.05).

Conclusion: Early BNP levels correlate with ultrasound blood flow parameters following liver transplantation, providing a foundation for evaluating cirrhotic cardiomyopathy. Patients with a poor short-term prognosis exhibit elevated BNP levels, altered dynamic circulation, and low-resistance blood flow

Key words: Ultrasonic imaging; BNP; Liver transplantation; Hemodynamics

Yu Huimin, Tang Ying, Niu Ningning, Wu Hongtao, Zhang Guoying, Wang Mingyang, Hao Xiaoye, Liu Jing. The Impact of B-type natriuretic peptide (BNP) on Transplanted Liver Hemodynamics and Short-Term Prognosis: A Single-Center Big Data Retrospective Study. Advanced Ultrasound in Diagnosis and Therapy, 2025, 9(2): 189-196.

Figures/Tables 6

Figure 1

Figure 2

Table 1

Table 2

Table 3

Table 4

References 20

[1]	Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo M, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998;27:28-34.
[2]	Rabie RN, Cazzaniga M, Salerno F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt. Am J Gastroenterol 2009;104:2458-2466.
[3]	Figiel W, Smoter P, Krasnodebski M, Rykowski P, Morawski M, Grat M, et al. The utility of early allograft dysfunction components in determining 90-day liver graft survival. Transplant Proc 2022;54:1017-1020.
[4]	Kelly R, Struthers AD.Are natriuretic PePtides clinially useful as markers of heart failure? Ann Clin Biochem 2001;38:575-583.
[5]	Januzzi JL, van Kimmenade R, Lainehbury J, Bayes-Genis A, Ordonez-Lianos J, Santalo-Bel M, et al. NT-ProBNP testing for diagnosis and short-term Prognosis in acute destabilized heart failure: an international Pooled analysis of 1256 Patients: the International Collaborative of NT-ProBNP Study. Eur Heart J 2006;27:330-337.
[6]	Ohuehi H, Takasugi H, Ohashi H, Okada Y, Yamada O, Ono Y, et al. Stratification of Pediatric heart failure on the basis of neurohormonal and cardiac autonomic nervous activties in patients with congenital heart disease. Circulation 2003;108:2368-2376.
[7]	Lin J, Zhang DL, Li TF.Correlation between Plasma concentration of brain natriuretie PePtide and cardiac function in patients with heart failure. J Cardiol (China) 2001;17:454-455.
[8]	Organ Transplant Branch of Chinese Medical Association.Technical Specifications for Ultrasound Imaging Diagnosis and Treatment of Organ Transplantation in China (2019 Edition). Organ Transplantation 2019;10:16-31.
[9]	Olthoff KM, Kulik L, Samstein B, Kaminski M, Abecassis M, Emond J, et al. Validation of a current Definition of early allograft dysfunction in liver transplant Recipients and analysis of risk factors. Liver Transpl 2010;16:943-949.
[10]	Liu H, Jayakumar S, Traboulsi M, Lee S. Cirrhotic cardiomyopathy: Implications for liver translation. Liver Transpl 2017;23:826-835.
[11]	Cahill PA, Redmond EM, Hodges R, Zhang S, Sitzmann JV. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996;25:370-378.
[12]	Moller S, Henriksen JH. Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15.
[13]	Yoon KT, Liu H,Lee SS Cirrhotic Cardiomyopathy. Curr Gastroenterol Rep 2020;22:45.
[14]	Bodzin AS, Baker TB. Liver translation today: where we are now and where we are going. Liver Transpl 2018;24:1470-1475.
[15]	Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris J, Hayes P. Cardiac function after orthotopic liver transplantation and the effects of immunosuppression: a prospective randomized trial comparing cyclosporine (Neoral) and tacrolimus. Liver Transpl 2002;8:690-700
[16]	Ningning Niu, Ying Tang, Mingyang Wang, Yao Yuan, Huimin Yu, Guoying Zhang, et al. Analysis of normal reference value range and influencing factors of hemodynamic ultrasound after adult liver transplantation. Chin J Ultrasound Imaging 2022;31:865-871.
[17]	Ying Tang, Guoying Zhang, Mingyang Wang, Tianchi Wang, Xiaochuan Liu, Pujing Liu, et al. Evaluation of normal changes of blood flow parameters of transplanted liver in early stage after living donor liver transplantation in children by Doppler ultrasound. Chin J Ultrasound Imaging 2020;29:673-678.
[18]	Atsushi Kitagawa, Norihiko Oka, Sumito Kimura, Hisashi Ando, Takashi Honda, Manabu Takanashi, et al. Clinical utility of the plasma brain natriuretic peptide level in monitoring tetralogy of fallot patients over the long term after initial intracardiac repair: considerations for pulmonary valve replacement. Pediatr Cardiol 2015;36:752-758.
[19]	Nakano Y, Kondo T, Osanai H, Murase Y, Nakashima Y, Asano H, et al. Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban. J Cardiol 2015;65:185-190.
[20]	Mingyang Wang, Ying Tang, Weina Kong, Ningning Niu, Guoying Zhang, Tianchi Wang, et al. Hemodynamic study in patients with early graft dysfunction after liver transplantation. Chin J Ultrasound Imaging 2023;32:608-613.

Indicators	PSV	EDV	RI	PI	PVV	BNP
Parameter 1	46.59 ± 20.59	13.55 ± 10.39	0.72 ± 0.24	1.18 ± 0.39	43.48 ± 16.98	1031 (456.41, 2484.74)
r value	-0.03	-0.45	-0.47	-0.60	-0.01	-
P value	0.34	0.01	0.01	0.00	0.72	-
Parameter 2	45.37 ± 19.51	13.64 ± 9.99	0.71 ± 0.14	1.15 ± 0.38	43.09 ± 16.76	997.7 (457.63, 2607.02)
r value	-0.01	-0.05	-0.41	-0.52	0.03	-
P value	0.74	0.16	0.03	0.01	0.45	-

Groups	Number of cases	PSV	EDV	RI	PI	PVV	BNP
Death group (1d)	27	58.51 ± 21.41	21.25 ± 15.39	0.67 ± 0.19	1.08 ± 0.51	37.33 ± 12.77	1838 (743.31, 6623.14)
Survival group (1d)	897	45.93 ± 19.33	13.16 ± 9.57	0.72 ± 0.24	1.18 ± 0.38	43.58 ± 17.00	1025 (446.42, 2407.51)
t/Z	-	-3.29	-3.06	-2.14	-2.13	-1.53	-2.07
P value	-	0.00	0.00	0.03	0.03	0.13	0.04
Death group (5d)	27	53.48 ± 19.24	20.32 ± 14.31	0.64 ± 0.16	0.98 ± 0.42	38.37 ± 10.69	1921 (631, 8042)
Survival group (5d)	897	45.11 ± 19.48	13.42 ± 9.81	0.71 ± 0.14	1.16 ± 0.38	43.21 ± 16.87	992.53 (453.94, 2550.57)
t/Z		-2.65	-3.13	-3.00	-2.92	-1.02	-2.10
P value		0.01	0.00	0.00	0.00	0.31	0.04

Groups	Number of cases	S/D (1d)	Number of cases	S/D (5d)
Death group	22	2.78 ± 1.06	24	2.64 ± 0.71
Survival group	782	3.57 ± 1.38	795	3.56 ± 1.82
Z value	-	-3.33		-3.47
P value	-	0.00		0.00

Groups	Ending		Total	χ² value	P value
Groups	Death	Survival	Total	χ² value	P value
Group A (1d)	5 (4.16%)	115 (95.83%)	120 (100%)	0.33	0.56
Group B (1d)	22 (2.74%)	782 (97.26%)	804 (100%)
Total	27 (2.92%)	897 (97.08%)	924 (100%)
Group A (5d)	3 (2.86%)	102 (97.14%)	105 (100%)	0.00	1.00
Group B (5d)	24 (2.93%)	795 (97.07%)	819 (100%)
Total	27 (2.92%)	897 (97.08%)	924 (100%)